Please assess the completion status of the following clinical trial:

Trial Title: Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children (1-17) and adults (18-75 years old);~* Relapsed or refractory adult and pediatric B-cell precursor ALL after HSCT;~* Evidence of CD19 tumor expression in bone marrow and/or peripheral blood by flow cytometry;~* Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening;~* No evidence of overall aGVHD \> Grade I or chronic GVHD (cGVHD) greater than mild at time of enrollment and in the previous 30 days;~* No longer taking immunosuppressive agents for at least 30 days prior to enrollment;~Exclusion Criteria:~* Patients with GVHD Grades II-IV;~* Any cell therapy in the last 30 days;

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CARCIK-CD19 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).